UNICREDIT BANK/PUT/ROCHE GS/250/0.1/18.09.24 | Real-time Bid/Ask 09:51:49 02/07/2024 pm IST | ||
| 0.9 EUR / 0.94 EUR | +16.46% |
|
| Current month | -9.20% | ||
| 1 month | -62.38% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ROCHE HOLDING AG
Latest news about ROCHE HOLDING AG
| Date | Price | Change |
|---|---|---|
| 02/24/02 | 0.89 | +12.66% |
| 01/24/01 | 0.79 | -9.20% |
| 28/24/28 | 0.87 | +6.10% |
| 27/24/27 | 0.82 | -4.65% |
| 26/24/26 | 0.86 | +26.47% |
Delayed Quote Börse Stuttgart
Last update July 02, 2024 at 09:28 pm IST
More quotesStatic data
| Product type | Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ROCHE HOLDING AG |
| Issuer | 
UniCredit
|
| WKN | HC9YB2 |
| ISIN | DE000HC9YB22 |
| Date issued | 16/10/2023 |
| Strike | 250 CHF |
| Maturity | 18/09/2024 (78 Days) |
| Parity | 10 : 1 |
| Emission price | 1.81 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.77 € |
|---|---|
| Lowest since issue | 0.66 € |
| Delta | -0.5x |
| Omega | 13.99 |
| Premium | 2.95x |
| Gearing | 28.1x |
| Moneyness | 1.006 |
| Difference Strike | 1.5 CHF |
| Difference Strike % | +0.60% |
| Spread | 0.04 € |
| Spread % | 4.30% |
| Theoretical value | 0.9100 |
| Implied Volatility | 18.41 % |
| Total Loss Probability | 46.84 % |
| Intrinsic value | 0.1544 |
| Present value | 0.7556 |
| Break even | 241.16 € |
| Theta | -0.04x |
| Vega | 0.05x |
| Rho | -0.03x |
Company Profile
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
Consensus: Roche Holding AG
Sell
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
250.1
CHF
Average target price
278.3
CHF
Spread / Average Target
+11.26%
- Stock Market
- Warrants
- Warrant
